

Annual Monitoring of Anticonvulsant, Carbamazepine

©2013 Truven Health Analytics Inc. Proprietary and confidential.

MEASURE DESCRIPTION:

Annual Monitoring of Anticonvulsant, Carbamazepine, indicates whether a patient, aged 18 years and older, who received at least 180 days of carbamazepine anticonvulsant medication during the measurement year, had at least one therapeutic monitoring event (lab test) during that same period. This measure excludes patients who had an inpatient stay during the measurement year.

This measure is based on the HEDIS measure *Annual Monitoring for Patients on Persistent Medications* (MPM).

PROPRIETARY STATUS: This measure is owned by NCQA [NQF-Endorsed TM].

CRITERIA REVISION

This measure is based on the HEDIS® 2013 Technical Specifications for Physician Measurement criteria. The NDC drug codes are from the NCQA files released November 2012.

CRITERIA REVIEW DATE: 03/29/2013

MEASURE TYPE: Quality - process of care

MEASURE PACKAGE: Advantage Nationally Endorsed

MINIMUM DATA REQUIREMENTS (months): 12

MEASURE DETAILS:

DENOMINATOR:

Identifies the unique count of patients, aged 18 years and older at the end of the measurement year, who received at least 180 treatment days of carbamazepine anticonvulsant medication during the measurement year. It excludes patients who had an inpatient stay during the measurement year.

At least 180 days supply of carbamazepine (during the measurement year)	NDC Codes as defined by NCQA (www.ncqa.org) And Days Supply \geq 180 when summed across all carbamazepine drug prescriptions. Only prescriptions filled during the measurement year are counted. Only the number of calendar days covered by prescriptions filled within the measurement year are counted. For example, a prescription for 90 days dispensed 30 days prior to the end of the reporting period has only 30 days counted.
AND	
Age in years (as of the end of the measurement year)	Age in Years \geq 18

EXCLUSIONS:

Excludes from the eligible population all patients who had an inpatient stay anytime during the measurement year. This includes admissions to hospitals, hospices, skilled nursing facilities, intermediate care facilities, rehabilitation facilities, and residential

psychiatric or substance abuse facilities.

Inpatient admission (acute, non-acute, or long-term care) (during the measurement year)	(Place of Service Code Medstat = 21, 25, 31, 32, 34, 51, 54, 55, 56, 61 Or Bill Type Code UB = 11*, 12*, 18*, 21*, 22*, 41*, 81*, 82*, 84* Or Revenue Code UB = 0115, 0118, 0125, 0128, 0135, 0138, 0145, 0148, 0155, 0158, 019*, 0650, 0655, 0656, 0658, 0659, 1001, 1002 Or HCPCS Procedure Code = H0017-H0019, T2048)
---	--

NUMERATOR:

Identifies patients, aged 18 years and older, who had at least one drug serum concentration monitoring test for carbamazepine during the measurement year.

At least one drug concentration test for carbamazepine (during the measurement year)	CPT Procedure Code = 80156, 80157
--	-----------------------------------

CONTINUOUS ENROLLMENT:

Continuously enrolled with medical and drug coverage during the measurement year, which equates to 12 months out of 12 months.

MEASURE BACKGROUND:

Adverse drug events can lead to hospital admissions. A meta-analysis estimated that in 1994 more than 1 million Americans were hospitalized because of adverse drug events, accounting for 4.7 percent of all admissions. In one survey, 25 percent of primary care outpatients reported an adverse drug event. The incidence of adverse events appears to increase with patients taking multiple drugs. Some adverse events are related to suboptimal laboratory monitoring. In one study, nearly half of all patients taking at least one chronic medication did not receive all of the laboratory tests recommended for monitoring, including drug levels for seizure medications, or renal function and electrolytes for patients taking ACE inhibitors, diuretics, or digoxin.

Treatment with an antiepileptic drug (AED) should be monitored regularly, including seizure frequency, side effects, and laboratory monitoring. Laboratory monitoring should include drug concentrations, blood counts, and hepatic and renal function. Drug levels should be checked at least yearly in stable patients. Drug levels can be used to determine the dose needed to maintain remission, assist in the diagnosis of AED toxicity, and assess compliance. It should be done more frequently with dose adjustments, changes in formulation of the AED, or changes in the patient's drug regimen, and during pregnancy.

AMA PCPI Notice of Use. Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for

noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

The Measures are provided as is without warranty of any kind. ©2007 American Medical Association. All Rights Reserved.

CPT® copyright 2012 American Medical Association. All rights reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Applicable FARS/DFARS restrictions apply to government use. CPT is a registered trademark of the American Medical Association.

The LOINC® codes, LOINC® table (regardless of format), LOINC® Release Notes, LOINC® Changes File, and LOINC® Users Guide are copyright© 1995-2012, Regenstrief Institute, Inc., and the Logical Observation Identifiers Names and Codes (LOINC) Committee. All rights reserved.

NCQA Notice of Use. Broad public use and dissemination of these measures is encouraged and the measure developers have agreed with NQF that noncommercial uses do not require the consent of the measure developer. Use by health care providers in connection with their own practices is not commercial use. Commercial use of a measure does require the prior written consent of the measure developer. As used herein, a • commercial use• refers to any sale, license, or distribution of a measure for commercial gain, or incorporation of a measure into any product or service that is sold, licensed, or distributed for commercial gain (even if there is no actual charge for inclusion of the measure).

These performance measures were developed and are owned by the National Committee for Quality Assurance (• NCQA•). These performance measures are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures. NCQA holds a copyright in this measure and can rescind or alter this measure at any time. Users of the measure shall not have the right to alter, enhance, or otherwise modify the measure and shall not disassemble, recompile, or reverse engineer the source code or object code relating to the measure. Anyone desiring to use or reproduce the measure without modification for a noncommercial purpose may do so without obtaining any approval from NCQA. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA.

© 2009-2012 National Committee for Quality Assurance. All rights reserved.

RED BOOK™ is a trademark of Truven Health Analytics Inc.
